BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
BDSI Products

Marketed Products

BDSI makes innovative therapies available.

BDSI offers a diverse portfolio of solutions for the treatment of chronic pain, acute migraine, and other serious and debilitating chronic conditions.

Pain Management:
Belbuca

BELBUCA®

BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA®) technology.

Contraindications
  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to buprenorphine

For more information on BELBUCA® visit www.belbuca.com

Medication Guide Full Prescribing Information

SYMPROIC®

Symproic® (naldemedine) is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.

Contraindications
  • Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction
  • Patients with a history of a hypersensitivity reaction to naldemedine

For more information on Symproic® visit www.symproic.com

Medication Guide Full Prescribing Information
Symprioc
Neurology:
Elyxyb

ELYXYB

ELYXYB Indication and Usage

ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

Limitations of Use: ELYXYB is not indicated for the preventive treatment of migraine.

Full Prescribing Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, 1-800-FDA-1088. Report an Adverse Event

BELBUCA®, BDSI®, and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. All other trademarks and trade names are the property of their respective owners.

Recent BDSI News

September 30, 2021

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Virtual Event on October 14, 2021 RALEIGH, N.C. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty

Read more
September 9, 2021

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022 Investor Day on October 14, 2021 RALEIGH, N.C. , Sept.

Read more
September 7, 2021

RALEIGH, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA ®  (buprenorphine buccal film), CIII

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
October 18, 2021BDSI $4.08/ - 1.75%
Data provided by Nasdaq. Minimum 15 minutes delayed.